SEC filing record
Primary Source · SEC.gov

INTRINSIC HEALTH PARTNERS II, L.P.

Fund Vehicle2022 vintageRule 506(b), Section 3(c), Section 3(c)(7)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalSold increasedForm D/A · 2026-07-084 events: 2 sold increased, 2 investors increasedLast filing 2026-07-08

Raised

$62M

Investors

84

Min Invest

$50,000

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

INTRINSIC HEALTH PARTNERS II, L.P. is a Delaware limited partnership that first filed a Form D on December 15, 2022 and most recently amended it on July 8, 2026, describing itself as a venture capital fund. The offering claims Rule 506(b), Section 3(c), Section 3(c)(7) and covers pooled investment fund interests. INTRINSIC HEALTH PARTNERS II, L.P. reported $62,374,000 sold from 84 investors in an offering of indefinite size as of the Form D filed July 8, 2026. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $50,000. The Form D names Cavu Securities LLC (CRD 6906); Frontier Solutions, LLC (CRD 136102); Thomas Herman (CRD 2234629), associated with Finalis Securities LLC; Stonehaven, LLC (CRD 118913) and 2 others as recipients of sales compensation. The issuer's address of record is Four Tower Bridge, 200 Barr Harbor Drive, Suite 400, Conshohocken, PA.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001956343
Entity NameINTRINSIC HEALTH PARTNERS II, L.P.
ExemptionRule 506(b), Section 3(c), Section 3(c)(7)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising. Section 3(c) of the Investment Company Act of 1940: the issuer is a pooled investment vehicle relying on an exclusion from registration as an investment company. Section 3(c)(7) of the Investment Company Act: the fund is excluded from investment-company registration because every investor is a qualified purchaser, generally an individual with at least $5 million in investments or an institution with at least $25 million.
Entity TypeLimited Partnership
Jurisdiction of OrganizationDelaware
Issuer AddressFour Tower Bridge, 200 Barr Harbor Drive, Suite 400, Conshohocken, PA
Phone(267) 678-0252
Industry / Fund TypePooled Investment Fund · Venture Capital Fund
Investment Company ActExcluded under Section 3(c)(7) (qualified purchasers only)
Securities TypePooled investment fund interests
First Sale DateDecember 2, 2022
Filing DateJuly 8, 2026
Accession Number0000911916-26-000040
Total Offering AmountIndefinite
Total Amount Sold$62,374,000
Total Investors84
Non-Accredited InvestorsNone
Minimum Investment$50,000
Offering DurationIntended to last more than one year
Revenue RangeDecline to Disclose
State (Issuer Address)PA
Amendment Count4 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

4

latest Jul 8, 2026

Critical / warning

0 / 0

2 watch · 2 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

1

raising

Latest event Sold increase · Jul 8, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Fund family Part of the Intrinsic Health Partners family: 2 vehicles across 1 generation · adviser of record Intrinsic Advisors, LLC · full family and the filing behind each link in the terminal

Investor

  • The full fund family and any related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
  • 4 filing events with values and deltas, latest 2026-07-08, and alerts on the next one
  • 1 offering timeline: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Adviser of Record (Form ADV)

Intrinsic Advisors, LLC

CRD 298804 · exempt reporting adviser · lists this fund on Schedule D 7.B.(1) as a venture capital fund

Auditor named on Form ADV: Cbiz Cpas P.C. · PCAOB-registered per the adviser

From the adviser's Form ADV as loaded from the SEC bulk data, joined on this issuer's Form D file number. Fund-level figures and the adviser's full fund roster are in the terminal.

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2026-07-08: 1 related person added and 0 removed against the filing of 2024-12-16; 5 now listed. The names are in the Terminal feed.

Intrinsic Health Partners GP II, LLC

Director · WEST CONSHOHOCKEN, PA

General Partner of Issuer

Gerald F. Stahlecker III

Director · WEST CONSHOHOCKEN, PA

Managing Member of Issuer's General Partner

Howard Goodwin M.D.

Director · WEST CONSHOHOCKEN, PA

Managing Member of Issuer's General Partner

Cornelius Merlini

Director · WEST CONSHOHOCKEN, PA

Managing Member of Issuer's General Partner

Christopher Edward Jung

Executive Officer · WEST CONSHOHOCKEN, PA

Chief Financial Officer of Issuer's General Partner

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Cavu Securities LLCCRD 6906 on BrokerCheck

New York, NY

Frontier Solutions, LLCCRD 136102 on BrokerCheck

Richmond, VA

Thomas HermanCRD 2234629 on BrokerCheck

Associated broker-dealer: Finalis Securities LLC (CRD 305908) · New York, NY

Stonehaven, LLCCRD 118913 on BrokerCheck

New York, NY · Soliciting in all states

Butler Capital Investments, LLCCRD 114242 on BrokerCheck

Oyster Bay, NY · Soliciting in all states

Hollister Associates, LLCCRD 173366 on BrokerCheck

Mount Pleasant, SC · Soliciting in all states

Questions About INTRINSIC HEALTH PARTNERS II, L.P.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is INTRINSIC HEALTH PARTNERS II, L.P.?

INTRINSIC HEALTH PARTNERS II, L.P. is a Delaware limited partnership that filed a Form D with the SEC on July 8, 2026 as a venture capital fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(7) for an offering of pooled investment fund interests.

Is INTRINSIC HEALTH PARTNERS II, L.P. legit?

AltStreet does not rate legitimacy; it reports the public record. INTRINSIC HEALTH PARTNERS II, L.P. filed a Form D with the SEC on July 8, 2026 claiming Rule 506(b), Section 3(c), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $62,374,000 sold to 84 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is INTRINSIC HEALTH PARTNERS II, L.P. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that INTRINSIC HEALTH PARTNERS II, L.P. claimed Rule 506(b), Section 3(c), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has INTRINSIC HEALTH PARTNERS II, L.P. raised?

INTRINSIC HEALTH PARTNERS II, L.P. reported $62,374,000 sold from 84 investors in an offering of indefinite size as of the Form D filed July 8, 2026.

Who can invest in INTRINSIC HEALTH PARTNERS II, L.P.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $50,000.

What is the minimum investment in INTRINSIC HEALTH PARTNERS II, L.P.?

The Form D lists $50,000 as the minimum investment accepted from any outside investor as of July 8, 2026. Issuers can waive their own minimums, and the figure does not include fees.

Who is selling INTRINSIC HEALTH PARTNERS II, L.P. and how are they paid?

The Form D names Cavu Securities LLC (CRD 6906); Frontier Solutions, LLC (CRD 136102); Thomas Herman (CRD 2234629), associated with Finalis Securities LLC; Stonehaven, LLC (CRD 118913) and 2 others as recipients of sales compensation.

Who is behind INTRINSIC HEALTH PARTNERS II, L.P.?

The Form D lists 5 related persons: Intrinsic Health Partners GP II, LLC, director (General Partner of Issuer); Gerald F. Stahlecker III, director (Managing Member of Issuer's General Partner); Howard Goodwin M.D., director (Managing Member of Issuer's General Partner); Cornelius Merlini, director (Managing Member of Issuer's General Partner); Christopher Edward Jung, executive officer (Chief Financial Officer of Issuer's General Partner). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is INTRINSIC HEALTH PARTNERS II, L.P. located?

The issuer's address on its SEC filings is Four Tower Bridge, 200 Barr Harbor Drive, Suite 400, Conshohocken, PA. Its phone number of record is 267.678.0252. It is organized under the laws of Delaware.

How long is the INTRINSIC HEALTH PARTNERS II, L.P. offering open?

The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 3 amendments are on record for this CIK.

How large is INTRINSIC HEALTH PARTNERS II, L.P.?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.